Skip to main content

Table 1 Patient, tumor, and treatment characteristics

From: A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer

Characteristic
Median age (range) 67 yr (39–91 yr)
Gender:
  Male 70 (73%)
  Female 26 (27%)
Primary tumor stage:
  Stage I 4 (4%)
  Stage II 6 (6%)
  Stage III 19 (20%)
  Stage IV 60 (63%)
  Unknown 7 (7%)
Prior definitive therapy:
  Radiation only 9 (9%)
  Chemo + radiation 11 (12%)
  Surgery + radiation 30 (31%)
  Chemo, surgery + radiation 46 (48%)
Median prior radiation to head and neck 70 Gy (36–139 Gy)
Median time from prior radiation to first recurrence 10 mo (1.4–188 mo)
Median time from prior radiation to SBRT 12 mo (2.4–179 mo)
Median SBRT dose 44 Gy (25–50 Gy)
Median tumor volume 26.3 cc (1–205 cc)
Use of cetuximab with SBRT 41 (43%)
Patients with other distant or untreated tumors 40 (42%)
Patients treated as adjuvant to surgery 7 (7%)
Sites treated with SBRT:
  Oral Cavity 15 (16%)
  Nasopharynx 7 (7%)
  Oropharynx 13 (14%)
  Hypopharynx 7 (7%)
  Larynx 7 (7%)
  Retropharynx 5 (5%)
  Neck 19 (20%)
  Base of Skull 10 (11%)
  Paranasal Sinuses 5 (5%)
  Other 8 (8%)
  1. Abbreviations: SBRT = stereotactic body radiation therapy.